Elad is a founding partner and lead scientist at Lunar Ventures. He also works as an investor across several technology companies, including Zenithon AI, iLoF, ElectricSQL, Zama, and deepset.
The Plymouth-based startup raised the capital from backers including Lunar Ventures and AlbionVC to increase manufacturing of its C-Star robots.
"We’re making the ocean’s eyes and ears, and we need a lot of them. Seventy per cent of the planet is ocean, and we can barely see any of it in real time. That’s not a sensing problem anymore; the technology works, and it works in the worst conditions on Earth. It’s a manufacturing problem"
— Anahita Laverack, Chief Executive and Co-Founder
The financing round was led by Lunar Ventures to support product commercialisation and clinical development.
"Menstruation is known as the fifth vital sign, but has historically been overlooked by the wearable sector, leaving millions without the data they need to understand and advocate for their own bodies. We envision a future where menstrual health is measured and understood as comprehensively as cardiovascular or metabolic health, giving people access to objective, actionable insights to better manage their health and wellbeing."
The investment round was led by Nauta with participation from LAUNCHub, Lunar Ventures, and Techstart.
"This funding accelerates our vision: applying synthetic data and Visual AI to solve the $800 billion problem of inefficiencies in CPG supply chains. We’re growing our computer vision engineering team and deepening our commercial footprint across the UK, European and US markets. Our platform is already a new benchmark for retail image recognition – this investment enables us to scale that impact globally."
The seed round was led by RTP Global with backing from Lunar Ventures and Hive Ventures.
"Unstructured data can be more analyzable, if AI is more accessible. At Instill AI we are committed to making this happen. We believe that machine learning and AI should be as easy to access as other off-the-shelf cloud services in the software industry today. This seed investment helps us speed up the development and strengthen the readiness of the VDP, bringing us one step closer to making the solution to this problem a reality."
The seed round was led by Faber with participation from international venture funds to support clinical trial operations.
"For hundreds of years, treatments have been developed with the assumption they will work for everyone. However, each person is different, and for many severe diseases such as Alzheimer’s, multiple factors can contribute to the effectiveness of a treatment on a given patient."